Please use this identifier to cite or link to this item:http://hdl.handle.net/20.500.12105/6552
A novel nano-immunoassay method for quantification of proteins from CD138-purified myeloma cells: biological and clinical utility
Haematologica. 2018; 103 (5) : 880 - 889.
Protein analysis in bone marrow samples from patients with multiple myeloma has been limited by the low concentration of proteins obtained after CD138+ cell selection. A novel approach based on capillary nano-immunoassay could make it possible to quantify dozens of proteins from each myeloma sample in an automated manner. Here we present a method for the accurate and robust quantification of the expression of multiple proteins extracted from CD138-purified multiple myeloma samples frozen in RLT Plus buffer, which is commonly used for nucleic acid preservation and isolation. Additionally, the biological and clinical value of this analysis for a panel of 12 proteins essential to the pathogenesis of multiple myeloma was evaluated in 63 patients with newly diagnosed multiple myeloma. The analysis of the prognostic impact of CRBN/Cereblon and IKZF1/Ikaros mRNA/protein showed that only the protein levels were able to predict progression-free survival of patients; mRNA levels were not associated with prognosis. Interestingly, high levels of Cereblon and Ikaros proteins were associated with longer progression-free survival only in patients who received immunomodulatory drugs and not in those treated with other drugs. In conclusion, the capillary nano-immunoassay platform provides a novel opportunity for automated quantification of the expression of more than 20 proteins in CD138+ primary multiple myeloma samples.
DIAGNOSED MULTIPLE-MYELOMA | CEREBLON EXPRESSION | GENE-EXPRESSION | WESTERN BLOTS | LENALIDOMIDE | IDENTIFICATION | THALIDOMIDE | RNA | POMALIDOMIDE | ABUNDANCE
This work was funded by a grant from the International Myeloma Foundation's Black Swan Research Initiative ®and“Gerencia Regional de Salud, Junta de Castilla y León” (BIO/SA35/14). WES™platform was acquired thanks to INNOCAMPUS Program (CEI10-1-0010